Bizarre Patents
Vehicular Impact Signaling Device
An apparatus for the deployment of a visible plume to alert other motorists that a proximate motor vehicle has been involved in a collision.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7959947 | Film coating A film coating composition suitable for use in coating pharmaceutical formulations comprising a) an acrylic polymer dispersion, e.g. an ethylacrylate/methylmethacrylate copolymer such as Eudragit NE30D, b) a surfactant, c) sodium stearyl fumarate, and d) a water-con... | 06/14/2011 |
| 7442387 | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) an... | 10/28/2008 |
| 7387791 | Liposome drug delivery This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal trac... | 06/17/2008 |
| 7357943 | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient The present invention relates to the field of pharmaceutical technology and describes a novel pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also r... | 04/15/2008 |
| 7316818 | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, a... | 01/08/2008 |
| 7316821 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 01/08/2008 |
| 7314638 | Preparing method for controlled released type tablet tamsulosin HCL and the tablet thereof The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredien... | 01/01/2008 |
| 7303763 | Compositions for conjugated estrogens and associated methods Oral conjugated estrogen formulations are disclosed and described. In one aspect, the oral formulation may be a tablet having a core and one or more coatings thereon. In addition to conjugated estrogen ingredients, the core may include one or more organic excipients... | 12/04/2007 |
| 7294347 | Coating compositions for bitterness inhibition The present invention discloses coating compositions with taste masking property, comprising a blend of pH sensitive polymers and optionally a pH independent polymer or a blend of the pH sensitive polymer and pH independent polymer used for taste masking of highly b... | 11/13/2007 |
| 7282218 | pH sensitive polymer for inhibiting transformation in drugs The present invention discloses a substantially amorphous pharmaceutical composition comprising a drug that can exist in a variety of polymorphic forms and a pH sensitive polymer, which inhibits the crystallization of the drug during formulation and reconstitution. ... | 10/16/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276250 | Sustained release formulations of oxymorphone Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of... | 10/02/2007 |
| 7270831 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains ... | 09/18/2007 |
| 7247313 | Polyacrylates coatings for implantable medical devices A coating for a medical device, particularly for a drug eluting stent, is described. The coating can include a polyacrylate, a blend of polyacrylates, or a blend of the polyacrylate with other polymers, for example, poly(ethylene-co-vinyl alcohol). ... | 07/24/2007 |
| 7235253 | Powder containing physiologically active peptide A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to ... | 06/26/2007 |
| 7229642 | Amino acid modulated extended release dosage form Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extr... | 06/12/2007 |
| 7229640 | Paroxetine controlled release compositions A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine. ... | 06/12/2007 |
| 7214387 | Sustained release formulations of metformin The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a p... | 05/08/2007 |
| 7211275 | Composite materials for controlled release of water soluble products Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materia... | 05/01/2007 |
| 7196059 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moi... | 03/27/2007 |
| 7195769 | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation... | 03/27/2007 |
| 7175873 | Rate limiting barriers for implantable devices and methods for fabrication thereof A method of coating an implantable medical device, such as a stent, is disclosed. The method includes applying a formulation on a first polymer layer containing a therapeutic substance to form a second layer. The formulation can contain a highly hydrophobic polymer ... | 02/13/2007 |
| 7169173 | Composite stent with regioselective material and a method of forming the same A composite stent and a method for making the same are provided. ... | 01/30/2007 |
| 7169178 | Stent with drug coating Coatings for stents that include a polymer and a drug are provided. A method of forming the coatings is also provided. ... | 01/30/2007 |
| 7160558 | Coating and binding agent for pharmaceutical formulations with improved storage stability The invention relates to a process for the preparation of a coating and binding agent for oral or dermal pharmaceutical forms, essentially consisting of (a) a copolymer consisting of free-radical-polymerized C1 to C4 esters of acrylic or methacrylic acid and further... | 01/09/2007 |
| 7157423 | Fumaric acid amides Fumaric acid amides of the general formula (I) wherein R1 represents OR3 or a D- or L-amino acid radical —NH—CHR4—COOH bonded via an amide bond, wherein R3 is hyd... | 01/02/2007 |
| 7147870 | Osmotic device containing pseudoephedrine and an H1 antagonist The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in th... | 12/12/2006 |
| 7132108 | Biodegradable and biocompatible polymeric microspheres encapsulating bacteria Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis are administered to chickens to provide the chickens with sustained protection against S. enteritidis infections. ... | 11/07/2006 |
| 7122204 | Antibiotic composition with inhibitor Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. I... | 10/17/2006 |
| 7108866 | Chronotherapeutic diltiazem formulations and the administration thereof A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of D... | 09/19/2006 |
| 7105180 | Stable galenic preparations comprising a benzimidazole and method for the production thereof The invention relates to a novel benzimidazole formulation and to a process for its production. The benzimidazole formulation comprises a layer comprising the benzimidazole compound together with an acidic reacting compound. ... | 09/12/2006 |
| 7094426 | Stable oral pharmaceutical dosage forms The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and p... | 08/22/2006 |
| RE39239 | Methods for treating early morning pathologies The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the... | 08/15/2006 |
| 7083807 | Pharmaceutical compositions for the controlled release of active substances The invention relates to pharmaceutical compositions which can be administrated orally, allowing the controlled release of at least one active substance comprising a) the said at least one active substance, b) between 5 and 60% by weight, r... | 08/01/2006 |
| 7074430 | Controlled release tramadol tramadol formulation A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient. ... | 07/11/2006 |
| 7070806 | Controlled release formulations coated with aqueous dispersions of acrylic polymers A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally... | 07/04/2006 |
| RE39149 | Method of administering azithromycin An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And ther... | 06/27/2006 |
| 7060293 | Powder-layered oral dosage forms An oral dosage form of morphine is formulated by powder-layering an homogeneous mixture of morphine sulfate and hydrous lactose impalpable onto inert beads to obtain a multiparticulate product. A plurality of the powder-layered beads may be administered either in im... | 06/13/2006 |
| 7060295 | Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (metformin) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, al... | 06/13/2006 |
| 7041316 | Stable oral pharmaceutical dosage forms The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and p... | 05/09/2006 |
